Shown to be highly effective in strengthening bones and protecting against fractures in all key sites, including hip and spine[1] Once-yearly dosing provides potential for compliance benefits and long ...

Once-yearly Aclasta Recommended In EU To Treat Male Osteoporosis And Reduce Risk Of New Fractures In Patients After Hip Fracture Male indication important as osteoporosis often neglected in men - ...

Aclasta reduced the risk of new spine fractures by 52% over six years versus patients who stopped treatment after three years[1] New data from six-year study validate Aclasta safety profile and ...

Aclasta has a demonstrated tolerability profile. The most common adverse events associated with Aclasta were transient post-dose symptoms such as fever and muscle pain. Most of these symptoms occurred ...

01 February 2009Single-dose therapy given once a year shown to provide significant bone protection benefits and may improve long-term treatment compliance Amman - Jordan - Aclasta (zoledronic acid 5 ...

Aclasta, a drug for the bone disorder Paget’s disease developed by Swiss drugmaker Novartis, is facing another delay in the USA after the Food and Drug Administration asked for more clinical data on ...

ZURICH (Reuters) - Novartis AG's Aclasta was more effective than Procter & Gamble Co's Actonel in increasing bone mass in patients with the bone-thinning disease osteoporosis, a study showed. A ...

Despite setbacks in the USA, Novartis’ Aclasta could yet be strong challenger to other bisphosphonate drugs in the treatment of both osteoporosis and Paget’s disease. Despite setbacks in the USA, ...

Basel, October 16, 2010 - Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Aclasta* (zoledronic acid 5 mg) in postmenopausal women ...